Drug Trial Radar · NCT05358717
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Jun 3, 2022
Primary completion
Feb 7, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
Conditions
- Huntington Disease
Interventions
PTC518Drug
PTC518 will be administered per dose and schedule specified in the arm.
PlaceboDrug
Placebo matching to PTC518 will be administered per schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Month 18
- Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3Time frame: Baseline, Month 3
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
University of California, San Diego
La Jolla, California
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston; McGovern Medical School
Houston, Texas
University of Washington Department of Neurology
Seattle, Washington
Monash Health
Clayton, Australia
Westmead Hospital
Sydney, Australia
Medical University Innsbruck
Innsbruck, Austria
The Ottawa Hospital, Parkinson's and Movement Disorders Clinic
Ottawa, Canada
Centre Hospitalier Universitaire d'Angers
Angers, France
Hôpital Universitaire de Marseille Hôpital de la Timone
Marseille, France
Brain and Spine Institute Paris
Paris, France
Charite University Medicine Berlin
Berlin, Germany
Ruhr-Univ. Bochum St. Joseph-Hospital
Bochum, Germany
George-Huntington-Institut
Münster, Germany
Ulm University, UKU, Dep. of Neurology
Ulm, Germany
Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica
Bologna, Italy
IRCCS Carlo Besta Neurological Institutte
Milan, Italy
IRCCS Casa Sollievo della Sofferenza Research Hospital
San Giovanni Rotondo, Italy
Leiden University Medical Center
Leiden, Netherlands
University of Otago, New Zealand Brain Research Institute
Christchurch, New Zealand
Hospital Universitario Cruces
Barakaldo, Spain
Hospital de la Santa Creu I Sant Pau
Barcelona, Spain
Hospital Universitario Burgos
Burgos, Spain
Hospital Ramón y Cajal
Madrid, Spain
The Barbery National Centre for Mental Health
Birmingham, United Kingdom
Cardiff University Schools of Medicine and Biosciences
Cardiff, United Kingdom
UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery
London, United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.